Traws Pharma, Inc.
38
3
4
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.8%
6 terminated/withdrawn out of 38 trials
81.3%
-5.3% vs industry average
11%
4 trials in Phase 3/4
8%
2 of 26 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (38)
Study of TRX-100 Tablets Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers
Role: lead
Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
Role: lead
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza
Role: lead
Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers
Role: lead
A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers
Role: lead
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
Role: lead
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
Role: collaborator
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Role: collaborator
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
Role: lead
Study of ON 123300 in Patients With Advanced Cancer
Role: lead
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Role: lead
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
Role: lead
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Role: lead
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Role: lead
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Role: collaborator
Three Dosing Schedules of Oral Rigosertib in MDS Patients
Role: lead
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Role: lead
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Role: lead
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Role: lead
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Role: lead